So Zydus would bring in additional competition so its important to note
Today Shaily reaching ATH, despite all the concerns from Oral Solids . Just FYI.
2 Likes
GLP-1 is the battlefield now in India..Onesource is a competitor of Shaily…existing players r scrambling to protect the turf…given the huge potential
4 Likes
Hi Nil
Shaily and Onesource are not competitors they serve different part of value chain one makes devices and other does fill finish Infact in many case, both are serving same customer
9 Likes
Means what…they hv the drugs + devices..they r filling the devices and selling them ..infact Novo also made the similar accusations..ultimately u need devices for drug delivery.
3 Likes
With last night tariff decisions on Pharma, how is Shaily placed to handle the tough situation.
Shaily Engineering Plastics has significant exposure to the US market through direct exports, US-based clients, and a recent major investment from a US fund.
Direct market presence
- Exports: Shaily is one of India’s largest exporters of plastic components, and the US has been its top export destination for a decade. The company has established warehouses in the US to facilitate just-in-time (JIT) deliveries to clients.
- Regulatory compliance: Shaily designs and manufactures products for regulated markets, including those that comply with US Food and Drug Administration (FDA) standards, demonstrating its ability to serve the American market.
- Healthcare segment: The company is significantly expanding its healthcare business, including commercializing injector pens in the US market. As of early 2025, commercial launches for new medical products were planned for the US in 2025 and 2026.
US-based clients
Shaily manufactures components and products for several major international brands, many of which have a strong presence in the US, including:
- Consumer goods: Procter & Gamble (P&G), Gillette, and Unilever.
- Home furnishings: IKEA.
- Appliances: GE Appliances.
- Healthcare: Several pharmaceutical and medical device companies.
Investment from US fund
In August 2025, the US-based investment management firm Capital Group acquired a 1.67% stake in Shaily Engineering Plastics, representing an investment of nearly Rs 148 crore. This significant investment indicates confidence from a major US financial institution in Shaily’s business.
4 Likes
Ely Lilly and Cipla sign marketing and distribution agreement for second brand of Tirzepatide in India. to be sold as ‘Yurpeak’, in addition to Lilly selling it under the Mounjaro brand name. This is to increase the reach of the drug in India.
Should be very beneficial for Shaily if this succeeds in expanding the market for Tirzepatide in India.
4 Likes
Why double digit drop in today’s opening. I couldn’t find any related news
seems like Dr. Reddy is a client of Shaily.
4 Likes
How big is the risk of Reddy not getting approval at all vs a reasonable delay?
a short-term sentiment drop in DRL’s Semaglutide program → negative sentiment spillover to Shaily.
Short-term effect Stock correction (due to sentiment, not fundamentals)
Long-term If DRL or others get approvals later, demand will likely recover
5 Likes
GLP-1 market is huge, incase you are rattled by 1 customer/1 Geo news..then one may regret later. One should wait for concall for any clarity…
2 Likes
Exactly. In fact, that’s the whole point of us looking for “picks and shovels” kind of businesses to take advantage of a big tailwind. And Shaily is a classic one in this regard!
The real danger to the thesis is if there comes along another oral drug that is equally or more effective, thereby negating the need for pens.
4 Likes
Wall Street Journal
Semi-AI wave in GLP -1 space. Novo Nordisk is trying to outbid, Pfizer in takeover with 9 BUSD offer !!..
Consolidated*
Revenue +34% YoY
Gross Profit Margin 59.3% vs 46.3% YoY
EBITDA +98% YoY
EBITDA Margin 31.8% vs 21.5% YoY
PBT +148% YoY
PAT +134% YoY
Segmental Revenue:-
Consumer 134.9 Cr (-3% YoY)
Healthcare 98.6 Cr (+163% YoY)
Industrial 23.2 Cr (+45% YoY)
→Volume of Polymers Processed (MT)
6,652 MT in Q2FY26 (+7.5% YoY)
→Machine utilization improved to 47.7% (up 560 bps YoY)
→ROCE 42.3% (vs 24.4% in Mar’25)
→ROE 32.7% (vs 18.5% in Mar’25)
Business Update:-
- Healthcare
→Installed 19 new machines during Q2FY26, expanding capacity for precision molding.
→Exhibited at CPHI Frankfurt, PDA Europe, and PODD Boston, holding 100+ meetings with potential clients.
→Launched “Shaily Axiom Max” – a fixed dose injection pen.
→Signed 4 new projects across GLP1 and other therapeutic categories.
-
Consumer
→New Business awarded for 5 new projects with 3 home furnishing customers -
Industrial
→New Business awarded for 1 new project with automotive customer
BUMPER RESULTS
6 Likes
Few key points from Concall
- Shaily GLP-1 has 23-24 partners total and in Canada partners between 3 to 4 out of 6 mostly who have filed/approval being sought
- Any probability of tie-up with a Innovator company on pens will be 100 million+ pens as a strategic thoughts(good inquiries during recent conferences), scale-up may be 3-4 yrs after tie-up
- Consumer Electronics scale-up may be 20 Mil to 100 Mil USD, quantum unknown at this point of time.May be set-up plant in vicinity of Customer plant. Not many Domestic companies possess this high precision capability
- Working on products for Semiconductors, some revenue may in come in Q4
- Plan is to gain meaningful market share in GLP1 rest of the world markets to thwart any Chinese competition
- Orals may be 25-30% of GLP1 markets (less efficacy till date )but pricing by Innovator will be prohibitive for growth in Rest of World
Disc : Invested for more than a year
9 Likes
@Zaki_Ahmad Please do not post only AI summaries in the forum. Remove all your earlier posts with AI only summaries.
4 Likes